Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial.
about
Rating scales for behavioral symptoms in Huntington's disease: Critique and recommendations.Therapeutic approaches to preventing cell death in Huntington diseaseCurrent Pharmacological Approaches to Reduce Chorea in Huntington's Disease.The sigma-1 receptor mediates the beneficial effects of pridopidine in a mouse model of Huntington diseaseBupropion for the treatment of apathy in Huntington's disease: A multicenter, randomised, double-blind, placebo-controlled, prospective crossover trial.The effect of mild and moderate renal impairment on the pharmacokinetics of pridopidine, a new drug for Huntington's disease.Managing juvenile Huntington's disease.Therapy in Huntington's disease: where are we?Dopamine imbalance in Huntington's disease: a mechanism for the lack of behavioral flexibility.The most appropriate primary outcomes to design clinical trials on Huntington's disease: meta-analyses of cohort studies and randomized placebo-controlled trials.The role of dopamine in Huntington's disease.Clinical trials in Huntington's disease: Interventions in early clinical development and newer methodological approaches.Diagnosis and treatment of chorea syndromes.Dopamine and Huntington's disease.Advancing pharmacotherapy for treating Huntington's disease: a review of the existing literature.Pridopidine for the treatment of Huntington's disease.Antipsychotic drugs in Huntington's disease.Pridopidine, a dopamine stabilizer, improves motor performance and shows neuroprotective effects in Huntington disease R6/2 mouse model.Dysregulation of Corticostriatal Connectivity in Huntington's Disease: A Role for Dopamine ModulationHuntington's Disease-Update on Treatments.Therapeutics in Huntington's Disease.Profile of pridopidine and its potential in the treatment of Huntington disease: the evidence to date.Pridopidine selectively occupies sigma-1 rather than dopamine D2 receptors at behaviorally active doses.Metoprolol-pridopidine drug-drug interaction and food effect assessments of pridopidine, a new drug for treatment of Huntington's disease.Pridopidine activates neuroprotective pathways impaired in Huntington Disease.The dopaminergic stabilizer pridopidine increases neuronal activity of pyramidal neurons in the prefrontal cortex.Pharmacokinetic and tolerability profile of pridopidine in healthy-volunteer poor and extensive CYP2D6 metabolizers, following single and multiple dosing.A randomized, double-blind, placebo-controlled trial of pridopidine in Huntington's disease.The pridopidine paradox in Huntington's disease.Tolerability and efficacy of the monoaminergic stabilizer (-)-OSU6162 (PNU-96391A) in Huntington's disease: a double-blind cross-over study.Resting-state connectivity and modulated somatomotor and default-mode networks in Huntington disease.Safety and Exploratory Efficacy at 36 Months in Open-HART, an Open-Label Extension Study of Pridopidine in Huntington's Disease.Treatment options for chorea.The dopaminergic stabilizers pridopidine and ordopidine enhance cortico-striatal Arc gene expression.Pridopidine Reverses Phencyclidine-Induced Memory Impairment.Pridopidine: Overview of Pharmacology and Rationale for its Use in Huntington's Disease.Therapy development in Huntington disease: From current strategies to emerging opportunities.Large-scale transcriptomic analysis reveals that pridopidine reverses aberrant gene expression and activates neuroprotective pathways in the YAC128 HD mouse.Huntington disease
P2860
Q30249645-8688B66E-D09F-4627-B585-2E7AB68B4E59Q34411338-D3D46E3C-F59E-4756-A0BD-25E2D015F22BQ34547558-D17A6124-1989-4452-8133-1D75CFB27C9DQ36183832-29DA21C1-8712-4132-9B2C-D6D8CBA2A8A8Q36316344-F328C02C-B2E4-4280-9881-85A9FD503DC6Q36802073-7D50FF6F-14CA-46FA-9804-0E177F608F87Q37443153-5240BDB7-04BB-47FB-895C-C32B88150B32Q38006434-332F1411-4BFB-4E25-8595-0B7D77528598Q38121068-B4DB7815-2DAB-41CC-BFB4-B9791F8E6523Q38202178-4A22638F-8C9E-4B54-99AA-1717BA162982Q38223504-541549FD-3643-450D-A37D-C3A77FA4F8B5Q38248689-2EE4D8B3-81F1-4928-A7ED-B6DB511CA42EQ38332316-66809223-A076-46D0-916B-F06BDEDBB9CDQ38379277-60D7C69A-59DD-4F9B-9DD4-234D381F5415Q38624994-4A60D063-9DA2-4AE5-AF7E-EDF332BF01BDQ38735562-C60C1EEA-DBA5-4B52-90E4-7AE18A388A35Q38830416-61D16AA8-0537-4939-940F-FE5FB9882FCAQ38861728-A93F6B0F-0D20-492F-82FB-EEA58DDB4BD3Q39041217-DE6E0E4B-79EC-401C-A0DC-4CE9BDE838A8Q39190617-EF8815BE-7C53-4573-922F-BBF315EB6451Q39252195-1A8B2A67-EA87-40CC-85E5-93EB0D320406Q40277912-DBBB8FE8-AECB-4F7D-AA37-1FD280BEC569Q40753593-B79B9A15-68FB-4D1E-9BE9-DC2A93367690Q41196024-A3A9A462-D3F4-4A0F-ABC2-90D3A2CA42FCQ42324179-60DB592C-95C7-4AB8-ABF2-A69EAA1EA3D8Q42435280-E5A7FEBB-FD4A-4D92-87AA-FB1D40C4DF87Q42666223-99445932-DAE7-46E8-9202-BC81E61CAE75Q45292205-DFF5B971-E20E-4369-B5B8-CF60F3EA3C8AQ45294030-A41E3103-D844-41DB-9EF5-AE72ADD9AED5Q45301837-C2714A21-B578-44B5-9705-5BADE6C11DFDQ45302003-3FBD9679-7D04-48EA-ACD8-74F99F02B5F0Q47694898-25ACD46D-D8AF-4B69-845C-ED96EE5AC8C2Q47977953-B1820FA9-E75B-4C4F-A59F-58DF0C6D554FQ51088282-EFBA7F66-5D4B-4048-B3B3-683FBA73C185Q52564664-621F7A3B-0839-40DE-AC91-355388A87444Q52685691-9D65A4F3-BC36-41A9-936E-02F5D71EC59DQ53716390-8D14B304-8517-4EF2-ADAA-11D6F233F7B2Q55335504-B0B6A0EE-FD67-484E-B3C0-1CE5195B2557Q56083219-152C036F-EF60-4238-8523-675D2B99FBFC
P2860
Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial.
description
2011 nî lūn-bûn
@nan
2011 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Pridopidine for the treatment ...... ind, placebo-controlled trial.
@ast
Pridopidine for the treatment ...... ind, placebo-controlled trial.
@en
Pridopidine for the treatment ...... ind, placebo-controlled trial.
@nl
type
label
Pridopidine for the treatment ...... ind, placebo-controlled trial.
@ast
Pridopidine for the treatment ...... ind, placebo-controlled trial.
@en
Pridopidine for the treatment ...... ind, placebo-controlled trial.
@nl
prefLabel
Pridopidine for the treatment ...... ind, placebo-controlled trial.
@ast
Pridopidine for the treatment ...... ind, placebo-controlled trial.
@en
Pridopidine for the treatment ...... ind, placebo-controlled trial.
@nl
P2093
P50
P921
P1433
P1476
Pridopidine for the treatment ...... ind, placebo-controlled trial.
@en
P2093
Alastair Sword
Asa Rembratt
Joakim Tedroff
Justo Garcia de Yebenes
Markus K Magnet
MermaiHD study investigators
P304
P356
10.1016/S1474-4422(11)70233-2
P577
2011-11-07T00:00:00Z